RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Approval history == The US FDA New Drug Application (NDA) was granted approval in May 2012, for use in adults. The US FDA Supplemental New Drug Application (sNDA) for pediatric use was granted approved in August 2014. In Israel, the Israeli Ministry of Health granted approval in September 2012. In Brazil, the Brazilian Health Surveillance Agency (ANVISA) granted approval in March 2013. In Canada, Health Canada issued a Notice of Compliance in May 2014, for both adults and pediatric patients. Taliglucerase alfa is made by the Israeli biotherapeutics company Protalix and sold by the American pharmaceutical company Pfizer.
In a letter to Crick on 11 December 1954, discussing how RNA could be produced from DNA since they contain fundamentally similar nucleotide compositions, he wrote: "I suspect the answer is staring us in the face." To solve the riddle of protein synthesis, Gamow (as the Synthesiser) created an informal team of scientists which he called the RNA Tide Club in 1954. As his prediction to denote 20 amino acids, the club could have only 20 members, with the designated officers: Crick (as the Pessimist), Rich (the Lord Privy Seal) and Watson (the Optimist) among them. It was meant partly to be humorous.
== Death == Kimon Georgiev died suddenly of a stroke at around 1 pm on 28 September 1969 at the rest station of the Council of Ministers in Varna, shortly after visiting the Varna Thermal Power Plant, which had opened a month earlier. He was buried on 30 September in the Central Sofia Cemetery with state honours, with Prime Minister Todor Zhivkov attending the ceremony.
Sources: en.wikipedia.org
=== 13 April === The Ukrainian Defence Ministry confirmed that Russian forces had reached the northern outskirts of Bohdanivka, ten kilometers from Chasiv Yar. Russia claimed to have taken Pervomaiske, 11 kilometers west of Avdiivka. Three people were killed in separate Russian attacks in Donetsk Oblast, while two people were killed in Kharkiv Oblast. One person was killed in a Russian attack on a car carrying humanitarian aid in Chernihiv Oblast. The Russian-installed head of Luhansk Oblast claimed that three people were injured in a Ukrainian missile attack on a factory in Luhansk city. Ukrainian officials claimed to have destroyed a major Russian headquarters using Storm Shadow missiles. Russian media later reported that Colonel Pavel Kropotov, commander of the 59th Guards Communications Brigade, was killed in the attack. The SBU announced that it had thwarted an assassination attempt against Kherson Oblast Governor Oleksandr Prokudin, adding that it had arrested a suspect who tried to launch a drone at his car. The IAEA reported that the Zaporizhzhia Nuclear Power Plant had been placed in a state of cold shutdown for the first time since October 2022. Germany announced that it would deliver another Patriot battery and additional missiles to Ukraine.
== External links == http://www.asap.unimelb.edu.au/asap_inf.htm – Australian Science Archives Project From http://www.asap.unimelb.edu.au/bsparcs/aasmemoirs AAS Biographical Memoirs (1966–1996) From http://www.sciencearchive.org.au "Fellows elected in 2005". Australian Academy of Science. Archived from the original on 25 March 2016. "Fellows elected in 2006". Australian Academy of Science. Archived from the original on 23 March 2016. "Fellows elected in 2007". Australian Academy of Science. Archived from the original on 1 April 2016. "Fellows elected in 2008". Australian Academy of Science. Archived from the original on 23 March 2016. "Fellows elected in 2009". Australian Academy of Science. Archived from the original on 24 September 2015. "Fellows elected in 2010". Australian Academy of Science. Archived from the original on 3 April 2016. "Fellows elected in 2011". Australian Academy of Science. Archived from the original on 24 September 2015. "Fellows elected in 2012". Australian Academy of Science.{{cite web}}: CS1 maint: deprecated archival service (link) "Fellows elected in 2013". Australian Academy of Science. Archived from the original on 25 March 2016. From https://www.science.org.au "Fellows elected in 2010". Australian Academy of Science. "Fellows elected in 2011". Australian Academy of Science. "Fellows elected in 2012". Australian Academy of Science. "Fellows elected in 2013". Australian Academy of Science. "Fellows elected in 2014". Australian Academy of Science. "Fellows elected in 2015". Australian Academy of Science. "Fellows elected in 2016".
Hydromorphone is a semi-synthetic μ-opioid agonist. As a hydrogenated ketone of morphine, it shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, and increased pinpoint constriction of the pupils.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.